PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

Clinical Neuropsychopharmacology and Addiction

1 Papers Indexed in Blossom

Data updated June 29, 2026

Research Footprint

Clinical Neuropsychopharmacology and Addiction has 1 tracked paper indexed in Blossom (2026) from 23 authors, most often covering Esketamine, across Treatment-Resistant Depression (TRD) and Depressive Disorders.

Published Papers

Open Accessindividual

Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study

This secondary analysis of the REAL-ESK study (n=210) examined intranasal esketamine in people with treatment-resistant depression and found that depression scores fell over three months in routine care. Men had slightly better antidepressant outcomes than women overall, while safety and stopping rates were similar between sexes.

Published
June 25, 2026
Journal
Clinical Neuropsychopharmacology and Addiction
Authors
Persico, L., d'Andrea, G., Cavallotto, C., Panichella, S., Santeusanio, A., Di Tullio, A., D'Angola, M., Rosati, A., Inserra, A., Tamagnini, G., Di Puorto, C., Salvi, V., Tripodi, B., De Berardis, D., Martiadis, V., Piccirillo, M., Raffone, F., Vannucchi, T., Barra, A., Lupi, M., Miotti, L., Di Cesare, A., Pettorruso, M.

Quick Facts

Papers Indexed
1
Open Access
Yes
Publisher
Scilight
Country
United Kingdom
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.